We have recently developed a new synthetic methodology that provided both N-aryl-5-hydroxytriazoles
and N-pyridine-4-alkyl triazoles. A selection of these products was carried through virtual screening
towards targets that are contemporary and validated for drug discovery and development. This study
determined a number of potential structure target dyads of which N-pyridinium-4-carboxylic-5-alkyl triazole
displayed the highest score specificity towards KAT2A. Binding affinity tests of abovementioned triazole
and related analogs towards KAT2A confirmed the predictions of the in-silico assay. Finally, we have
run in vitro inhibition assays of selected triazoles towards KAT2A; the ensemble of binding and inhibition
assays delivered pyridyl-triazoles carboxylates as the prototype of a new class of inhibitors of KAT2A